Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

60 Press Releases
DateTitleCompany
19 Apr 16 CSL Behring Marks World Hemophilia Day by Donating IUs of Its Specialty Biotherapeutics for Bleeding Disorders to World Federation of Hemophilia CSL Behring ,
Published by
PharmiWeb.com
19 Mar 16 CSL Behring sponsors IDF webinar series for young adults living with primary immunodeficiencies CSL Behring ,
Published by
PharmiWeb.com
09 Mar 16 CSL Behring Awards LEAD Grants to Help Rare Disease Patient Groups Achieve Their Advocacy Objectives CSL Behring,
Published by
PR Newswire
25 Feb 16 First Export of Privigen® From New Manufacturing Facility in Broadmeadows, Melbourne, Australia CSL Behring,
Published by
PharmiWeb.com
04 Feb 16 CSL Behring and Its Employees Pass $1 Million Mark in Charitable Donations to Communities Throughout the U.S. CSL Behring ,
Published by
PharmiWeb.com
22 Dec 15 CSL Behring Submits Marketing Authorization Application to the European Medicines Agency for rVIII-SingleChain for Patients with Hemophilia A CSL Behring,
Published by
PR Newswire
22 Dec 15 CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients CSL Behring ,
Published by
PharmiWeb.com
21 Dec 15 CSL Behring Submits New Drug Application to Japan's Pharmaceuticals and Medical Devices Agency for rIX-FP for Hemophilia B Patients CSL Behring,
Published by
PR Newswire
21 Dec 15 CSL CEO Says Corporate Responsibility And Sustainability Are All About Continuous Improvement CSL Limited,
Published by
PharmiWeb.com
10 Dec 15 CSL Behring Expands Operations to Russia CSL Behring ,
Published by
PharmiWeb.com
07 Dec 15 CSL Behring Presents Phase III Data for Its Long-Acting Recombinant Factor IX Albumin Fusion Protein for Hemophilia B at the 57th ASH Annual Meeting & Exposition CSL Behring,
Published by
PR Newswire
02 Dec 15 CSL Behring to Present New Data for rIX-FP and rVIII-SingleChain at the 57th ASH Annual Meeting & Exposition CSL Behring,
Published by
PR Newswire
01 Dec 15 CSL opens UK Seqirus office CSL Limited Seqirus,
Published by
Ruder Finn UK for Seqirus
16 Nov 15 CSL brands world's no. 2 influenza vaccine provider as Seqirus CSL ,
Published by
PharmiWeb.com
17 Sep 15 CSL Plasma Donates 60 Bicycles To Boys And Girls Club, Broward County CSL Plasma Inc.,
Published by
PR Newswire
10 Sep 15 Centers for Medicare and Medicaid Services Extends New Technology Add-On Payment for CSL Behring’s Kcentra® for Third Year CSL Behring ,
Published by
PharmiWeb.com
25 Aug 15 CSL Behring Receives Marketing Authorization for Respreeza® in Europe CSL Behring ,
Published by
Pharmiweb.com
25 Aug 15 CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors CSL Behring ,
Published by
Pharmiweb.com
29 Jun 15 CSL Behring Receives Positive CHMP Opinion for Respreeza® (human alpha-1 proteinase inhibitor) as Maintenance Treatment for Patients with Severe Alpha-1 Antitrypsin Deficiency in Europe CSL Behring,
Published by
Business Wire
30 Mar 15 European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients CSL BEHRING,
Published by
PR Newswire
22 May 15 National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award CSL Behring,
Published by
PR Newswire
14 May 15 Science Information And Technology Driving Evolution Of Global Healthcare CSL Behring,
Published by
PR Newswire
01 Jun 15 Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD) CSL Behring,
Published by
PR Newswire
25 Aug 15 CSL Behring Enrolls First Patient in Global Phase II/III Study of rVIIa-FP for On-Demand Treatment of Patients with Hemophilia A or B with Inhibitors CSL Behring,
Published by
PR Newswire
04 Feb 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for rIX-FP for Hemophilia B Patients CSL BEHRING,
Published by
PR Newswire
16 Jun 15 CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress CSL Behring,
Published by
PR Newswire
27 Feb 15 CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia CSL BEHRING,
Published by
PR Newswire
28 Jul 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A CSL Behring,
Published by
PR Newswire
28 Jul 15 Swissmedic Accepts for Review CSL Behring's MAA for rIX-FP for Patients with Hemophilia B CSL Behring,
Published by
PR Newswire
29 Jul 15 U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A CSL Behring ,
Published by
PharmiWeb.com
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.